Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2008

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Autoimmune Diseases
Interventions
DRUG

Efalizumab

1 mg/kg of efalizumab administered sub q once weekly

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT00777400 - Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells | Biotech Hunter | Biotech Hunter